Kitano, S., Shimizu, T., Koyama, T., Ebata, T., Iwasa, S., Kondo, S., . . . Sims, T. (2020). Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemother Pharmacol.
Chicago-stil citatKitano, Shigehisa, et al. "Dose Exploration Results From Phase 1 Study of Cemiplimab, a Human Monoclonal Programmed Death (PD)-1 Antibody, in Japanese Patients With Advanced Malignancies." Cancer Chemother Pharmacol 2020.
MLA-referensKitano, Shigehisa, et al. "Dose Exploration Results From Phase 1 Study of Cemiplimab, a Human Monoclonal Programmed Death (PD)-1 Antibody, in Japanese Patients With Advanced Malignancies." Cancer Chemother Pharmacol 2020.